Press release
Cluster Headache Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
(Albany, US) On October 28, 2026, DelveInsight's "Cluster Headache Market Insights, Epidemiology and Market Forecast - 2036" report provides comprehensive insights into the Cluster Headache market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type, and examines the market drivers and barriers shaping the space.
Discover the latest drugs and treatment options in the Cluster Headache Pipeline @ https://www.delveinsight.com/report-store/cluster-headache-market [https://www.delveinsight.com/report-store/cluster-headache-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
Key Takeaways from the Cluster Headache Report
*
In August 2026, Ceruvia Lifesciences raised USD 8 million to finalize an integrated Phase 1/2 clinical trial of its proprietary non-hallucinogenic LSD analog, which is being evaluated as a targeted treatment for cluster headache without psychedelic side effects.
*
According to DelveInsight's analysis, there were nearly 890,000 total prevalent cases of cluster headache in the 7MM in 2025, with the highest number in the US.
*
Galcanezumab (EMGALITY, Eli Lilly) is currently the only FDA-approved targeted therapy for episodic cluster headache, approved in June 2019.
*
The therapeutic pipeline remains highly limited, with few significant candidates in active clinical development, underscoring a substantial unmet need for novel preventive and acute treatments.
*
Leading Cluster Headache companies include Eli Lilly, Ceruvia Lifesciences, and others.
*
Promising therapies include galcanezumab (EMGALITY) and Ceruvia's non-hallucinogenic LSD analog, among others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Cluster Headache Treatment Drugs [https://www.delveinsight.com/report-store/cluster-headache-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
Cluster Headache Overview
Cluster headache is an uncommon, severe form of primary neurovascular headache and the most common type of trigeminal autonomic cephalalgia, affecting approximately 0.1% of the population, with a marked male predominance. It is considered one of the most painful conditions known, with attacks of intense one-sided pain centered on the eye or temple. Attacks occur in cluster periods lasting weeks to months, followed by remission. Episodic cluster headache involves cluster periods of 7 days to 1 year separated by remission of at least 1 month, while chronic cluster headache persists for more than 1 year with no remission or remission under 1 month. Onset most commonly occurs around age 30. Hypothalamic dysfunction, trigeminal nerve activation, genetic predisposition, smoking, and alcohol are considered contributing factors, and a first-degree relative with the condition raises risk 14 to 39 times. Treatment includes acute therapies (high-flow oxygen and triptans), preventive therapies (verapamil, corticosteroids, lithium, topiramate, and CGRP-targeting agents), and transitional therapies, with prevention as the primary goal.
Common symptoms include:
*
Severe, one-sided orbital, supraorbital, or temporal pain
*
Tearing (lacrimation) and conjunctival redness
*
Nasal congestion
*
Eyelid swelling
*
Facial sweating
*
Restlessness during attacks
Cluster Headache Emerging Drugs Profile
Galcanezumab (EMGALITY): Eli Lilly Galcanezumab is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a key mediator in headache pathophysiology. Administered subcutaneously, it is the first and only FDA-approved CGRP-targeting antibody for both migraine and episodic cluster headache. The FDA approved the 300 mg injection for episodic cluster headache in adults in June 2019, following its September 2018 approval for preventive treatment of migraine. Currently, the drug is marketed.
Non-Hallucinogenic LSD Analog: Ceruvia Lifesciences Ceruvia's proprietary non-hallucinogenic LSD analog is being developed as a targeted treatment for cluster headache, aiming to provide significant relief without triggering psychedelic side effects. Currently, the drug is in an integrated Phase 1/2 trial.
Explore groundbreaking therapies and clinical trials in the Cluster Headache Pipeline @ New Cluster Headache Treatment Drugs [https://www.delveinsight.com/report-store/cluster-headache-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
Cluster Headache Market Drivers
*
Better understanding of pathophysiology: Advances in understanding the hypothalamus, trigeminal-autonomic pathways, and CGRP have enabled targeted therapies.
*
Strong unmet need: The lack of effective preventive and acute options is driving research into CGRP-targeted therapies, neuromodulation, and novel agents targeting neuroinflammatory and hypothalamic pathways.
*
Growing awareness and diagnosis: Greater disease awareness, improved diagnosis, and better access to specialized care are expanding the treated population.
*
Large patient base: Nearly 890,000 prevalent cases in the 7MM, with US cases expected to grow over the forecast period.
*
Proven CGRP mechanism: The success of galcanezumab validates CGRP as a target and encourages further development.
*
Investment in novel approaches: Funding rounds such as Ceruvia's signal growing interest in non-traditional approaches for cluster headache.
Cluster Headache Market Barriers
*
Limited pipeline: Few significant candidates are in active clinical development, which constrains near-term market expansion.
*
Rarity of the disease: Affecting about 0.1% of the population, the small patient pool makes recruitment and commercial scale difficult.
*
Sparse clinical evidence: Few large-scale controlled trials exist, and many therapies rely on smaller studies.
*
Delayed diagnosis and misdiagnosis: Overlap with migraine, trigeminal neuralgia, and other headache disorders can delay appropriate treatment.
*
Limited long-term preventive options: Established options such as verapamil, lithium, and corticosteroids have tolerability limits, and attack freedom is hard to achieve in chronic disease.
*
Reliance on established low-cost therapies: Oxygen, triptans, and generic preventives set a high bar for new entrants.
*
Only one approved targeted therapy: Approval is limited to episodic cluster headache, leaving chronic cluster headache without an approved targeted option.
Download DelveInsight's in-depth Cluster Headache report today! @ Cluster Headache Companies [https://www.delveinsight.com/report-store/cluster-headache-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
The Cluster Headache Report Provides Insights Into
*
Companies developing and marketing Cluster Headache therapies, with aggregate therapies per company
*
Candidates segmented into early-, mid-, and late-stage development
*
Active and inactive (dormant or discontinued) projects
*
Drugs by stage, route of administration, target, monotherapy vs. combination, mechanism of action, and molecule type
*
Collaborations (company-company and company-academia), licensing agreements, and financing details
*
Cluster Headache Market drivers, barriers, and unmet needs
Cluster Headache Companies Eli Lilly, Ceruvia Lifesciences, and others.
Route of Administration: Subcutaneous, Oral, Inhalation
Molecule Types: Monoclonal antibody, Small molecule
Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Cluster Headache Market Drivers and Barriers [https://www.delveinsight.com/report-store/cluster-headache-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr]
Scope of the Cluster Headache Report
*
Coverage: 7MM (US, EU4, UK, Japan)
*
Companies: As listed above
*
Therapies: Galcanezumab (EMGALITY), Ceruvia's non-hallucinogenic LSD analog, and others
*
Assessment by Product Type: Mono, Combination, Mono/Combination
*
Assessment by Clinical Stage: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Contents
*
Introduction
*
Executive Summary
*
Cluster Headache: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III): None currently
*
Mid Stage Products (Phase II): Ceruvia LSD analog (Phase 1/2)
*
Early Stage Products (Phase I): Ceruvia LSD analog (Phase 1/2)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Key Companies
*
Key Products
*
Unmet Needs
*
Market Drivers and Barriers
*
Future Perspectives and Conclusion
*
Analyst Views
*
Appendix
*
About Us
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cluster-headache-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: +19193216187
Address:304 S. Jones Blvd #2432 NV 89107
City: Albany
State: New York
Country: India
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cluster Headache Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4675673 • Views: …
More Releases from ABNewswire
Acute Pancreatitis Market is Projected to Grow by 2034 Owing to the Development …
The market dynamics for Acute Pancreatitis are expected to evolve during the forecast period, driven by the growing burden of acute pancreatic inflammation, increasing demand for effective disease management, and the need for therapies that address severe and recurrent episodes.
(Albany, New York) - October 28, 2026 - The market dynamics for Acute Pancreatitis are expected to evolve during the forecast period, driven by the growing burden of acute pancreatic inflammation,…
Joseph Hoskins' New Novel Sam Dickens Explores Love, Regret, and the Choices Tha …
Paris, Texas - October 28, 2026 - Author Joseph Hoskins presents Sam Dickens , a character-driven novel that follows a young man's experiences with family conflict, forbidden affection, personal mistakes, and the challenges of adulthood. Combining dark humor with emotional storytelling, the novel examines how decisions made during youth can influence the course of an entire lifetime.
The story begins with Sam, a high school student struggling with poor grades, family…
Adult Myopia Market is Projected to Grow by 2036 Owing to the Rising Prevalence …
The market dynamics for Adult Myopia are expected to evolve during the forecast period, driven by the rising prevalence of myopia, increasing awareness of vision-related complications, and growing demand for effective disease management. Additionally, the development of novel pharmacological approaches and advancements in the treatment of myopic choroidal neovascularization (mCNV) are expected to shape the market.
(Albany, New York) - October 28, 2026 - The market dynamics for Adult Myopia are…
Autoimmune Uveitis Market and Pipeline Appear Robust With Key Pharma Companies A …
The Autoimmune Uveitis market analysis report delivers important insights into ongoing research on pipeline Autoimmune Uveitis drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
(Albany, US) On October 28, 2026, DelveInsight's "Autoimmune Uveitis Market Insights, Epidemiology and Market Forecast - 2036" report provides comprehensive insights into the Autoimmune Uveitis market and pipeline landscape across the 7MM. It covers marketed and emerging drug profiles, including clinical and nonclinical stage products. It also…
More Releases for Cluster
Global Cluster Munitions Market Size by Application, Type, and Geography: Foreca …
According to Market Research Intellect, the global Cluster Munitions market under the Aerospace and Defense category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
Ongoing geopolitical tensions, military arsenal upgrading, and regional wars are driving slow expansion of the cluster munitions business. Some…
Global Automotive Instrument Cluster Market
All of the top selling models in Europe feature hybrid instrument cluster.
The 2 wheelers are sold in high numbers in Asia region, account for a sizeable instrument cluster market volume in the region.
The digital instrument cluster market accounts for a small share of the market but has been growing at the fastest rate,especially in China.
VW now offers biggest range of Digital instrument cluster starting from Polo, Golf, to…
Instrument Cluster Market | Robert Bosch GmbH, launched the world’s first curv …
A clear and precise display of information is vital for the driver to ensure a safe and comfortable ride. The different types of instrument clusters have been witnessing increasing traction in the automobile sector, as they provide attractive and accurate information to keep the driver vigilant while driving. Instrument cluster is a driver information system that combines vital details, such as vehicle speed, traffic condition, and amount of fuel available,…
Boise State University Reduces HPC Cluster Operating Costs with Bright Cluster M …
University found Bright Cluster Manager to be less expensive than open source HPC cluster management tool-kits
Bright Computing announced today that Boise State University researchers selected Bright Cluster Manager® for their collaboration research cluster R1, a powerful computer system that drives interdisciplinary computational research. Boise State University research projects span chemistry, biology, physics and pharmacology, with particular emphasis on advancing novel methods in molecular targeted therapeutics for cancer research. Bright Cluster…
Bright Cluster Manager Selected For HPC Cluster Research Grant at St. Louis Univ …
Bright Computing today announced that Bright Cluster Manager® 6.0 was selected as part of an HPC cluster research grant awarded to St. Louis University (SLU). The university is the winner of a high-performance computer cluster donated by Silicon Mechanics, and its vendor partners Bright Computing, AMD, Kingston Technologies, NVIDIA, QLogic, Supermicro and Seagate.
Bright Cluster Manager is increasingly the solution of choice for academic institutions looking to minimize system management…
Bright Cluster Manager chosen for TOP500-class HPC Cluster in France
Consortium led by the University of Bordeaux 1 and including leading universities, research institutes in southwest France purchase 3,168-core supercomputer comprising technology from Dell, Intel and Bright Computing
San Jose, California — Bright Computing, a leader in cluster management software, announced today that the company has been selected to provide the cluster management solution for a French research consortium’s new supercomputer. The HPC cluster, to be installed by ClusterVision at…
